Strategies to Reduce the Risk of Contrast-Induced Nephropathy

American Journal of Cardiology

Volumn 98, Issue 6 SUPPL. 1, 2006, Pages 59-77

  Stacul, Fulvio ^a   Adam, Andy ^b   Becker, Christoph R ^c   Davidson, Charles ^d   Lameire, Norbert ^e   McCullough, Peter A ^f   Tumlin, James ^g  

^a UNIVERSITY OF TRIESTE   (Italy)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f WILLIAM BEAUMONT HOSPITAL   (United States)

^g Southeast Renal Research Institute SERRI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMINOPHYLLINE; AMLODIPINE; ARGININE; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; BICARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; DIURETIC AGENT; DOPAMINE; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; FELODIPINE; FENOLDOPAM; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MANNITOL; METFORMIN; MISOPROSTOL; NIFEDIPINE; NITRENDIPINE; PROSTAGLANDIN E1; THEOPHYLLINE;

ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CRYSTALLOID; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FLUID INTAKE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYDRATION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; META ANALYSIS; METABOLIC ACIDOSIS; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW;

CONSENSUS DEVELOPMENT CONFERENCES; CONTRAST MEDIA; EMERGENCIES; FLUID THERAPY; HEMOFILTRATION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; RENAL DIALYSIS; RENAL INSUFFICIENCY, ACUTE;

EID: 33747880514     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.01.024     Document Type: Article

References (117)

1. Byrd L.H., Sherman R.L., Stenzel K.H., and Rubin A.L. Computerized tomography-induced acute renal failure [letter]. Arch Intern Med 139 (1979) 491
2. Chen W.Y., Yen T.S., Cheng J.T., Hsieh B.S., and Hsu F.Y. Acute renal failure following intravenous pyelography. Taiwan Yi Xue Hui Za Zhi 69 (1970) 229-233
3. Dudzinski P.J., Petrone A.F., Persoff M., and Callaghan E.E. Acute renal failure following high dose excretory urography in dehydrated patients. J Urol 106 (1971) 619-621
4. Kamdar A., Weidmann P., Makoff D.L., and Massry S.G. Radiography dye induced acute renal failure in diabetes mellitus. [abstract]. Kidney Int 10 (1976) 501
5. Pillay V.K., Robbins P.C., Schwartz F.D., and Kark R.M. Acute renal failure following intravenous urography in patients with long-standing diabetes mellitus and azotemia. Radiology 95 (1970) 633-636
6. Eisenberg R.L., Bank W.O., and Hedgock M.W. Renal failure after major angiography can be avoided with hydration. AJR Am J Roentgenol 136 (1981) 859-861
7. Teruel J.L., Marcen R., Herrero J.A., Felipe C., and Ortuno J. An easy and effective procedure to prevent radiocontrast agent nephrotoxicity in high-risk patients [letter]. Nephron 51 (1989) 282
8. Louis B.M., Hoch B.S., Hernandez C., Namboodiri N., Neiderman G., Nissenbaum A., Foti F.P., Magno A., Banayat G., Fata F., Manohar N.L., and Lipner H.I. Protection from the nephrotoxicity of contrast dye. Ren Fail 18 (1996) 639-646
9. Mueller C., Buerkle G., Buettner H.J., Petersen J., Perruchoud A.P., Eriksson U., Marsch S., and Roskamm H. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 162 (2002) 329-336
10. Tumlin J., Stacul F., Adam A., Becker C.R., Davidson C., Lameire N., McCullough P.A., and CIN Consensus Working Panel. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 98 suppl 6A (2006) 14K-20K
11. Merten G.J., Burgess W.P., Gray L.V., Holleman J.H., Roush T.S., Kowalchuk G.J., Bersin R.M., Van Moore A., Simonton III C.A., Rittase R.A., Norton H.J., and Kennedy T.P. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291 (2004) 2328-2334
12. Bader B.D., Berger E.D., Heede M.B., Silberbaur I., Duda S., Risler T., and Erley C.M. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?. Clin Nephrol 6 (2004) 1-7
13. Krasuski R.A., Beard B.M., Geoghagan J.D., Thompson C.M., and Guidera S.A. Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J Invasive Cardiol 15 (2003) 699-702
14. Taylor A.J., Hotchkiss D., Morse R.W., and McCabe J. PREPARED: Preparation for Angiography in Renal Dysfunction-a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 114 (1998) 1570-1574
15. Trivedi H.S., Moore H., Nasr S., Aggarwal K., Agrawal A., Goel P., and Hewett J. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 93 (2003) C29-C34
16. Russo D., Minutolo R., Cianciaruso B., Memoli B., Conte G., and De Nicola L. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 6 (1995) 1451-1458
17. Tumlin J.A., Wang A., Murray P.T., and Mathur V.S. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 143 (2002) 894-903
18. Stevens M.A., McCullough P.A., Tobin K.J., Speck J.P., Westveer D.C., Guido-Allen D.A., Timmis G.C., and O'Neill W.W. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. study. J Am Coll Cardiol 33 (1999) 403-411
19. Baker C.S., Wragg A., Kumar S., De Palma R., Baker L.R., and Knight C.J. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 41 (2003) 2114-2118
20. Schindler R., Stahl C., Venz S., Ludat K., Krause W., and Frei U. Removal of contrast media by different extracorporeal treatments. Nephrol Dial Transplant 16 (2001) 1471-1474
21. Donnelly P.K., Burwell N., McBurney A., Ward J.W., Walls J., and Watkin E.M. Hemodialysis and iopamidol clearance after subclavian venography. Invest Radiol 28 (1993) 629-632
22. Furukawa T., Ueda J., Takahashi S., and Sakaguchi K. Elimination of low-osmolality contrast media by hemodialysis. Acta Radiol 37 (1996) 966-971
23. Moon S.S., Back S.E., Kurkus J., and Nilsson-Ehle P. Hemodialysis for elimination of the nonionic contrast medium iohexol after angiography in patients with impaired renal function. Nephron 70 (1995) 430-437
24. Lehnert T., Keller E., Gondolf K., Schaeffner T., Pavenstaedt H., and Schollmeyer P. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant 13 (1998) 358-362
25. Sterner G., Frennby B., Kurkus J., and Nyman U. Does post-angiographic hemodialysis reduce the risk of contrast-medium nephropathy?. Scand J Urol Nephrol 34 (2000) 323-326
26. Huber W., Jeschke B., Kreymann B., Hennig M., Page M., Salmhofer H., Eckel F., Schmidt U., Umgelter A., Schweigart U., and Classen M. Haemodialysis for the prevention of contrast-induced nephropathy: outcome of 31 patients with severely impaired renal function, comparison with patients at similar risk and review. Invest Radiol 37 (2002) 471-481
27. Frank H., Werner D., Lorusso V., Klinghammer L., Daniel W.G., Kunzendorf U., and Ludwig J. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol 60 (2003) 176-182
28. Vogt B., Ferrari P., Schonholzer C., Marti H.P., Mohaupt M., Wiederkehr M., Cereghetti C., Serra A., Huynh-Do U., Uehlinger D., and Frey F.J. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 111 (2001) 692-698
29. Marenzi G., Marana I., Lauri G., Assanelli E., Grazi M., Campodonico J., Trabattoni D., Fabbiocchi F., Montorsi P., and Bartorelli A.L. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 349 (2003) 1333-1340
30. Abizaid A.S., Clark C.E., Mintz G.S., Dosa S., Popma J.J., Pichard A.D., Satler L.F., Harvey M., Kent K.M., and Leon M.B. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 83 (1999) 260-263
31. Erley C.M., Duda S.H., Schlepckow S., Koehler J., Huppert P.E., Strohmaier W.L., Bohle A., Risler T., and Osswald H. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 45 (1994) 1425-1431
32. Erley C.M., Duda S.H., Rehfuss D., Scholtes B., Bock J., Muller C., Osswald H., and Risler T. Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 14 (1999) 1146-1149
33. Gandhi M.R., Brown P., Romanowski C.A., Morcos S.K., Campbell S., el Nahas A.M., and Gray T.A. The use of theophylline, an adenosine antagonist in the prevention of contrast media induced nephrotoxicity [letter]. Br J Radiol 65 (1992) 838
34. Huber W., Ilgmann K., Page M., Hennig M., Schweigart U., Jeschke B., Lutilsky L., Weiss W., Salmhofer H., and Classen M. Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology 223 (2002) 772-779
35. Huber W., Schipek C., Ilgmann K., Page M., Hennig M., Wacker A., Schweigart U., Lutilsky L., Valina C., Seyfarth M., Schomig A., and Classen M. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 91 (2003) 1157-1162
36. Kapoor A., Kumar S., Gulati S., Gambhir S., Sethi R.S., and Sinha N. The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transplant 17 (2002) 1936-1941
37. Katholi R.E., Taylor G.J., McCann W.P., Woods Jr. W.T., Womack K.A., McCoy C.D., Katholi C.R., Moses H.W., Mishkel G.J., Lucore C.L., et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 195 (1995) 17-22
38. Kolonko A., Wiecek A., and Kokot F. The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol 11 (1998) 151-156
39. Huber W., Jeschke B., Page M., Weiss W., Salmhofer H., Schweigart U., Ilgmann K., Reichenberger J., Neu B., and Classen M. Reduced incidence of radiocontrast-induced nephropathy in ICU patients under theophylline prophylaxis: a prospective comparison to series of patients at similar risk. Intensive Care Med 27 (2001) 1200-1209
40. Shammas N.W., Kapalis M.J., Harris M., McKinney D., and Coyne E.P. Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. J Invasive Cardiol 13 (2001) 738-740
41. Ix J.H., McCulloch C.E., and Chertow G.M. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant 19 (2004) 2747-2753
42. Cooling D.S. Theophylline toxicity. J Emerg Med 11 (1993) 415-425
43. Attallah N., Yassine L., Musial J., Yee J., and Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol 62 (2004) 273-278
44. Wolfrum S., Jensen K.S., and Liao J.K. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 23 (2003) 729-736
45. Khanal S., Attallah N., Smith D.E., Kline-Rogers E., Share D., O'Donnell M.J., and Moscucci M. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 118 (2005) 843-849
46. Spargias K., Alexopoulos E., Kyrzopoulos S., Iokovis P., Greenwood D.C., Manginas A., Voudris V., Pavlides G., Buller C.E., Kremastinos D., and Cokkinos D.V. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 110 (2004) 2837-2842
47. Gurkowski L., MacDougall M., and Wiegmann T. Effects of misoprostol on contrast-induced renal dysfunction. Am J Ther 2 (1995) 837-842
48. 1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media?. Nephrol Dial Transplant 15 (2000) 43-49
49. 1: a randomized, double-blind, placebo-controlled study. Am J Ther 8 (2001) 155-162
50. Agrawal M., Wodlinger A.M., Huggins C.E., Tudor G.E., Pieper J.A., O'Reilly K.P., Denu-Ciocca C.J., Stouffer G.A., and Ohman E.M. Effect of N-acetylcysteine on serum creatinine concentration in patients with chronic renal insufficiency who are undergoing coronary angiography. Heart Drug 4 (2004) 87-91
51. Allaqaband S., Tumuluri R., Malik A.M., Gupta A., Volkert P., Shalev Y., and Bajwa T.K. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 57 (2002) 279-283
52. Azmus A.D., Gottschall C., Manica A., Manica J., Duro K., Frey M., Bulcao L., and Lima C. Effectiveness of acetylcysteine in prevention of contrast nephropathy. J Invasive Cardiol 17 (2005) 80-84
53. Boccalandro F., Amhad M., Smalling R.W., and Sdringola S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 58 (2003) 336-341
54. Briguori C., Manganelli F., Scarpato P., Elia P.P., Golia B., Riviezzo G., Lepore S., Librera M., Villari B., Colombo A., and Ricciardelli B. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 40 (2002) 298-303
55. Briguori C., Colombo A., Airoldi F., Violante A., Castelli A., Balestrieri P., Paolo Elia P., Golia B., Lepore S., Riviezzo G., et al. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 44 (2004) 762-765
56. Briguori C., Colombo A., Violante A., Balestrieri P., Manganelli F., Paolo E.P., Golia B., Lepore S., Riviezzo G., Scarpato P., et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 25 (2004) 206-211
57. Diaz-Sandoval L.J., Kosowsky B.D., and Losordo D.W. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 89 (2002) 356-358
58. Drager L.F., Andrade L., Barros de Toledo J.F., Laurindo F.R.M., Machado-Cesar L.A., and Seguro A.C. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant 19 (2004) 1803-1807
59. Durham J.D., Caputo C., Dokko J., Zaharakis T., Pahlavan M., Keltz J., Dutka P., Marzo K., Maesaka J.K., and Fishbane S. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 62 (2002) 2202-2207
60. Efrati S., Dishy V., Averbukh M., Blatt A., Krakover R., Weisgarten J., Morrow J.D., Stein M.C., and Golik A. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int 64 (2003) 2182-2187
61. Fung J.W., Szeto C.C., Chan W.W., Kum L.C., Chan A.K., Wong J.T., Wu E.B., Yip G.W., Chan J.Y., Yu C.M., Woo K.S., and Sanderson J.E. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis 43 (2004) 801-808
62. Gill N.K., Piccione E.A., Vido D.A., Clark B.A., and Shannon R.P. Gender as a risk factor for contrast nephropathy: effects of hydration and N-acetylcysteine. Clin Cardiol 27 (2004) 554-558
63. Goldenberg I., Shechter M., Matetzky S., Jonas M., Adam M., Pres H., Elian D., Agranat O., Schwammenthal E., and Guetta V. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: a randomized controlled trial and review of the current literature. Eur Heart J 25 (2004) 212-218
64. Kay J., Chow W.H., Chan T.M., Lo S.K., Kwok O.H., Yip A., Fan K., Lee C.H., and Lam W.F. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 289 (2003) 553-558
65. Kefer J.M., Hanet C.E., Boitte S., Wilmotte L., and De Kock M. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient?. Acta Cardiol 58 (2003) 555-560
66. MacNeill B.D., Harding S.A., Bazari H., Patton K.K., Colon-Hernadez P., DeJoseph D., and Jang I.K. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv 60 (2003) 458-461
67. Miner S.E.S., Dzavik V., Nguyen-Ho P., Richardson R., Mitchell J., Atchison D., Seidelin P., Daly P., Ross J., McLaughlin P.R., et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J 148 (2004) 690-695
68. Ochoa A., Pellizzon G., Addala S., Grines C., Isayenko Y., Boura J., Rempinski D., O'Neill W., and Kahn J. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. J Interv Cardiol 17 (2004) 159-165
69. Oldemeyer J.B., Biddle W.P., Wurdeman R.L., Mooss A.N., Cichowski E., and Hilleman D.E. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J 146 (2003) E23
70. Rashid S.T., Salman M., Myint F., Baker D.M., Agarwal S., Sweny P., and Hamilton G. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg 40 (2004) 1136-1141
71. Raven Q.L., Walton T., Howe A.M., and Macon E.J. Role of acetylcysteine in the prevention of contrast-media-induced nephrotoxicity. Am J Health Syst Pharm 60 (2003) 2232-2235
72. Shyu K., Cheng J.T., and Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 40 (2002) 1383-1388
73. Tadros G.M., Mouhayar E.N., Akinwande A.O., Campbell B., Wood C., and Blankenship J.A. Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography. J Invasive Cardiol 15 (2003) 311-314
74. Tepel M., van der Giet M., Schwarzfeld C., Laufer U., Liermann D., and Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343 (2000) 180-184
75. Webb J.G., Pate G.E., Humphries K.H., Buller C.E., Shalansky S., Al Shamari A., Sutander A., Williams T., Fox R.S., and Levin A. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 148 (2004) 422-429
76. Pannu N., Manns B., Lee H., and Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 65 (2004) 1366-1374
77. Alonso A., Lau J., Jaber B.L., Weintraub A., and Sarnak M.J. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 43 (2004) 1-9
78. Birck R., Krzossok S., Markowetz F., Schnuelle P., van der Woude F.J., and Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 362 (2003) 598-603
79. Guru V., and Fremes S.E. The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy. Clin Nephrol 62 (2004) 77-83
80. Isenbarger D.W., Kent S.M., and O'Malley P.G. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 92 (2003) 1454-1458
81. Bagshaw S.M., and Ghali W.A. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med 2 (2004) 38
82. Misra D., Leibowitz K., Gowda Ramesh M., Shapiro M., and Khan Ijaz A. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clin Cardiol 27 (2004) 607-610
83. Kshirsagar A.V., Poole C., Mottl A., Shoham D., Franceschini N., Tudor G., Agrawal M., Denu-Ciocca C., Magnus Ohman E., and Finn W.F. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 15 (2004) 761-769
84. Nallamothu B.K., Shojania K.G., Saint S., Hofer T.P., Humes H.D., Moscucci M., and Bates E.R. Is acetylcysteine effective in preventing contrast-related nephropathy?. A meta-analysis. Am J Med 117 (2004) 938-947
85. Hoffmann U., Fischereder M., Krueger B., Drobnik W., and Kraemer B.K. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 15 (2004) 407-410
86. Hans S.S., Hans B.A., Dhillon R., Dmuchowski C., and Glover J. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. Am Surg 64 (1998) 432-436
87. Hans B., Hans S.S., Mittal V.K., Khan T.A., Patel N., and Dahn M.S. Renal functional response to dopamine during and after arteriography in patients with chronic renal insufficiency. Radiology 176 (1990) 651-654
88. Kapoor A., Sinha N., Sharma R.K., Shrivastava S., Radhakrishnan S., Goel P.K., and Bajaj R. Use of dopamine in prevention of contrast induced acute renal failure-a randomised study. Int J Cardiol 53 (1996) 233-236
89. Hall K.A., Wong R.W., Hunter G.C., Camazine B.M., Rappaport W.A., Smyth S.H., Bull D.A., McIntyre K.E., Bernhard V.M., and Misiorowski R.L. Contrast-induced nephrotoxicity: the effects of vasodilator therapy. J Surg Res 53 (1992) 317-320
90. Weisberg L.S., Kurnik P.B., and Kurnik B.R. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 45 (1994) 259-265
91. Gare M., Haviv Y.S., Ben-Yehuda A., Rubinger D., Bdolah-Abram T., Fuchs S., Gat O., Popovtzer M.M., Gotsman M.S., and Mosseri M. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol 34 (1999) 1682-1688
92. Chamsuddin A.A., Kowalik K.J., Bjarnason H., Dietz C.A., Rosenberg M.S., Gomes M.D., McDermott C.M., and Hunter D.W. Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy. AJR Am J Roentgenol 179 (2002) 591-596
93. Kini A.A., and Sharma S.K. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Rev Cardiovasc Med 29 suppl 1 (2001) S19-S25
94. Kini A.S., Mitre C.A., Kamran M., Suleman J., Kim M., Duffy M.E., Marmur J.D., and Sharma S.K. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol 89 (2002) 999-1002
95. Kini A.S., Mitre C.A., Kim M., Kamran M., Reich D., and Sharma S.K. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Catheter Cardiovasc Interv 55 (2002) 169-173
96. Madyoon H., Croushore L., Weaver D., and Mathur V. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interv 53 (2001) 341-345
97. Stone G.W., McCullough P.A., Tumlin J.A., Lepor N.E., Madyoon H., Murray P., Wang A., Chu A.A., Schaer G.L., Stevens M., Wilensky R.L., O'Neill W.W., and CONTRAST Investigators. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 290 (2003) 2284-2291
98. Cacoub P., Deray G., Baumelou A., and Jacobs C. No evidence for protective effects of nifedipine against radiocontrast-induced acute renal failure. Clin Nephrol 29 (1988) 215-216
99. Khoury Z., Schlicht J.R., Como J., Karschner J.K., Shapiro A.P., Mook W.J., and Weber R.J. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy 15 (1995) 59-65
100. Russo D., Testa A., Della Volpe L., and Sansone G. Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker. Nephron 55 (1990) 254-257
101. Madsen J.K., Jensen J.W., Sandermann J., Johannesen N., Paaske W.P., Egeblad M., and Pedersen E.B. Effect of nitrendipine on renal function and on hormonal parameters after intravascular iopromide. Acta Radiol 39 (1998) 375-380
102. Carraro M., Mancini W., Artero M., Stacul F., Grotto M., Cova M., and Faccini L. Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. Nephrol Dial Transplant 11 (1996) 444-448
103. Neumayer H.H., Junge W., Kuefner A., and Wenning A. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant 4 (1989) 1030-1036
104. Spangberg-Viklund B., Berglund J., Nikonoff T., Nyberg P., Skau T., and Larsson R. Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function?. Scand J Urol Nephrol 30 (1996) 63-68
105. Arici M., Usalan C., Altun B., Erdem Y., Yasavul U., Turgan C., Kes S., and Caglar S. Radiocontrast-induced nephrotoxicity and urinary alpha-glutathione S-transferase levels: effect of amlodipine administration. Int Urol Nephrol 35 (2003) 255-261
106. Kurnik B.R., Weisberg L.S., Cuttler I.M., and Kurnik P.B. Effects of atrial natriuretic peptide versus mannitol on renal blood flow during radiocontrast infusion in chronic renal failure. J Lab Clin Med 116 (1990) 27-36
107. Kurnik B.R., Allgren R.L., Genter F.C., Solomon R.J., Bates E.R., and Weisberg L.S. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 31 (1998) 674-680
108. Miller H.I., Dascalu A., Rassin T.A., Wollman Y., Chernichowsky T., and Iaina A. Effects of an acute dose of l-arginine during coronary angiography in patients with chronic renal failure: a randomized, parallel, double-blind clinical trial. Am J Nephrol 23 (2003) 91-95
109. Solomon R., Werner C., Mann D., D'Elia J., and Silva P. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331 (1994) 1416-1420
110. Weinstein J.M., Heyman S., and Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 62 (1992) 413-415
111. Anto H.R., Chou S.Y., Porush J.G., and Shapiro W.B. Mannitol prevention of acute renal failure (ARF) associated with infusion intravenous pyelography (IIVP). [abstract]. Clin Res 27 (1979) 407A
112. Anto H.R., Chou S.Y., Porush J.G., and Shapiro W.B. Infusion intravenous pyelography and renal function: effect of hypertonic mannitol in patients with chronic renal insufficiency. Arch Intern Med 141 (1981) 1652-1656
113. Old C.W., Duarte C.G., Siedlecki M., Lehrner L.M., Henry A.R., and Sinnott R.C. Effects of mannitol in the prevention of radiocontrast (RC) acute renal failure (ARF) in patients with pre-existing chronic renal failure (CRF). [abstract]. Kidney Int 21 (1982) 158
114. Cruz C., Hricak H., Samhouri F., Smith R.F., Eyler W.R., and Levin N.W. Contrast media for angiography: effect on renal function. Radiology 158 (1986) 109-112
115. Wang A., Holcslaw T., Bashore T.M., Freed M.I., Miller D., Rudnick M.R., Szerlip H., Thames M.D., Davidson C.J., Shusterman N., and Schwab S.J. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 57 (2000) 1675-1680
116. Morcos S.K., and Thomsen H.S. European Society of Urogenital Radiology guidelines on administering contrast media. Abdom Imaging 28 (2003) 187-190
117. Heupler Jr. F.A., and Members of the Laboratory Performance Standards Committee of the Society for Cardiac Angiography and Interventions. Guidelines for performing angiography in patients taking metformin. Cathet Cardiovasc Diagn 43 (1998) 121-123